Ascendis Pharma A/S (NASDAQ:ASND) Shares Purchased by abrdn plc

abrdn plc lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 18.3% during the fourth quarter, Holdings Channel reports. The fund owned 187,180 shares of the biotechnology company’s stock after buying an additional 28,967 shares during the quarter. abrdn plc’s holdings in Ascendis Pharma A/S were worth $25,769,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth $30,000. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the third quarter valued at $60,000. Blue Trust Inc. grew its position in Ascendis Pharma A/S by 540.5% during the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock valued at $76,000 after buying an additional 427 shares during the period. GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Signaturefd LLC grew its position in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period.

Ascendis Pharma A/S Trading Up 5.9 %

NASDAQ:ASND opened at $129.41 on Thursday. The company’s 50-day moving average price is $133.13 and its 200-day moving average price is $132.65. The company has a market cap of $7.85 billion, a P/E ratio of -16.02 and a beta of 0.64. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00.

Analyst Ratings Changes

Several analysts recently commented on the stock. JPMorgan Chase & Co. raised their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Stifel Nicolaus raised their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Wedbush restated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $191.57.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.